Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2025
186
Period ended Dec 31, 2025
Change on a year earlier
+27.4%
146 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 186 | +27.4% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 146 | +22.7% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 119 | +33.7% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 89 | +2,125.0% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 4 | -94.6% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 74 | +17.5% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 63 | +50.0% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 42 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up zerbaxa (ceftolozane and tazobactam) — u.s. sales ($m)
Cite this data
StockData. (2026). Merck Zerbaxa (ceftolozane and tazobactam) — U.S. sales ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_zerbaxa_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.